...archers at the UC Davis M.I.N.D. Institute have fo...ited unusual exploration of objects long before be...h risk for developing autism, the researchers foun...r were more likely to spin, repetitively rotate, s...at simple objects, including a baby bottle and a r...
...s of American adults are aware of the importance o...teps to eat a healthy diet and engage in exercise,...nationwide consumer opinion survey, Nutrition and ...1, ADA has used respondents, answers to a number o...ree groups representing people,s overall attitudes...
...2008 -- Billions of tons of carbon sequestered in ...tmosphere in the coming decades as a result of glo...terplay between peat bogs, water tables, and clima...a small percentage of the carbon locked away in th...de carbon, scientists at Harvard University, Worce...
Other Biology News:Unusual use of toys in infancy a clue to later autism 2Unusual use of toys in infancy a clue to later autism 3American Dietetic Association releases 2008 nutrition trends survey 2Global warming predicted to hasten carbon release from peat bogs 2(Date:11/19/2009)...wswire-FirstCall/ -- Omeros Corporation (Nasdaq: ... for the third quarter ended September 30, 2009. F...os reported a net loss of $3.9 million, or $1.34 p...n, or $2.54 per share, for the same period in 2008...e Company reported a net loss of $15.5 million, or...
(Date:11/19/2009)...Md., Nov. 19 Spherix Inc...hnology for diabetes therapy, and a provider of te..., supplement, biotechnology and pharmaceutical com...eported $6.3 million registered direct placement t...ts common stock and warrants to purchase up to 1,1...
(Date:11/19/2009)... Spherix Incorporated (N...diabetes therapy, and a provider of technical and ..., biotechnology and pharmaceutical companies, toda...g of Shareholders. ,, At the meeting, sharehold...ed the following members to the Board of Directors...
(Date:11/19/2009)...y, November 19 MONITORING FORCE Gm..., 2009 Flibanserin in the,indication treatment-rel...isease for orphan drug status designation with the...d dyskinesia is a complication of the mainstay,tre...n to some of those,affected, since it may be disab...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2...aq:,PURE), creators of the patented antimicrobial,...evenues for the fiscal year ended July 31, 2008 of...ed with $336,400 in the,prior fiscal year. The Com...of $(6,540,300), or $(0.24) per share, compared wi...n the prior year., (Logo: http://www.newscom.com...
...xpanding Industry Connections, MOUNTAINSIDE, N.J....ndependent, full-service medical education company...ice President, Business,Development., Weinstein w...nd,publishing as the head of Business Development....lication Sales at McMahon Publishing., "Todd brin...
...aq:,CPHD) today announced the U.S. Food & Drug Adm...MRSA/SA Skin and Soft Tissue Infection (SSTI) test...atory Improvement Amendments,(CLIA). The new test ...-resistant Staphylococcus aureus (MRSA) and Staphy...tive) in SSTIs. Xpert MRSA/SA SSTI,runs on Cepheid...
Other Biology Technology:PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 4Econo Gradient Pump Rack, preassembled from Bio-Rad
...R-101 Labeled Substrates (red fluorescence; Ex=590...rotease activation • No lysing, fixing, or pe...e cell-permeable, fluorescently labeled inhibitors...sin-like activity in whole living cells. Select fr...
... with FAM-Labeled Substrate (green fluorescence; E...ine protease activation • No lysing, fixing, ...tilize cell-permeable, fluorescently labeled inhib...otrypsin-like activity in whole living cells. Sele...
... with FAM-Labeled Substrate (green fluorescence; E...ine protease activation • No lysing, fixing, ...tilize cell-permeable, fluorescently labeled inhib...otrypsin-like activity in whole living cells. Sele...
Biology Products: